AMX 342
Alternative Names: AMX-342Latest Information Update: 09 Feb 2022
Price :
$50 *
At a glance
- Originator Amunix
- Class Antisense oligonucleotides; Drug conjugates; Hepatoprotectants; Peptides; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lipodystrophy; Non-alcoholic steatohepatitis; Somatotropin deficiency
Most Recent Events
- 17 Jan 2022 Amunix has been acquired by Sanofi
- 28 Aug 2021 No recent reports of development identified for research development in Lipodystrophy in USA
- 28 Aug 2021 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in USA